secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0000950170-24-092735
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines Q2 net loss $133M; advances RMC-6236 toward Phase 3 in PDAC
--------------------------------------------------------------------------------

- Q2 net loss $133.2M vs $98.3M YoY; revenue zero due to Sanofi collaboration termination.
- Cash $1.59B; projects funding into 2027; FY 2024 GAAP net loss guidance $560-600M.
- RMC-6236 in PDAC: median PFS 8.1 months (KRAS G12X); Phase 3 RASolute 302 planned for 2L this year.
- Board appoints Frank Clyburn, former Merck Keytruda leader; new senior hires in medical affairs.
- R&D expenses $134.9M vs $98.0M; G&A $21.7M vs $14.6M, driven by clinical and commercial prep.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000095017024092735/0000950170-24-092735-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000095017024092735/rvmd-20240805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-092735

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer